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The accumulation of LDL-derived cholesterol in the
artery wall is the initiating event that causes athero-
sclerosis. However, the mechanisms that lead to
the initiation of atherosclerosis are still poorly under-
stood. Here, by using endothelial cell-specific trans-
genesis of the caveolin-1 (Cav-1) gene in mice, we
show the critical role of Cav-1 in promoting athero-
genesis. Mice were generated lacking Cav-1 and
apoE but expressing endothelial-specific Cav-1 in
the double knockout background. Genetic ablation
of Cav-1 on an apoE knockout background inhibits
the progression of atherosclerosis, while re-expres-
sion of Cav-1 in the endothelium promotes lesion
expansion. Mechanistically, the loss of Cav-1
reduces LDL infiltration into the artery wall, promotes
nitric oxide production, and reduces the expression
of leukocyte adhesion molecules, effects completely
reversed in transgenic mice. In summary, this unique
model provides physiological evidence supporting
the important role of endothelial Cav-1 expression
in regulating the entry of LDL into the vessel wall
and the initiation of atherosclerosis.
INTRODUCTION
Atherosclerosis is a chronic inflammatory process involving
complex interactions ofmodified lipoproteins,monocyte-derived
macrophages or foam cells, T lymphocytes, endothelial cells
(ECs), smooth muscle cells, and fibroblasts (Glass and Witztum,
2001). The accumulation of LDL-derived cholesterol in the artery
wall is the initial event that leads to atherosclerosis, yet themech-
anisms involved in LDL trafficking through the endothelium
remain unclear (Vasile et al., 1983). Vascular permeability to
LDL can occur via either a transcellular or a paracellular pathway
(Frank et al., 2004). One potential transcellular pathway may48 Cell Metabolism 10, 48–54, July 8, 2009 ª2009 Elsevier Inc.occur through caveolae since caveolae are the prominent plas-
malemmal vesicles found in the vascular endothelium in vivo.
Caveolae are 50–100 nm flask-shaped invaginations of plasma
membrane, and caveolin-1 (Cav-1) is essential for caveolae
biogenesis in endothelium, thus orchestrating Cav-1-dependent
intracellular trafficking and signal transduction (Liu et al., 2002).
The roles of Cav-1 and its family members, Cav-2 and Cav-3,
have been studied through the generation of various knockout
mice. Cav-1 knockout mice exhibit a complete absence of cav-
eolae in all Cav-1-expressing tissues, while mice lacking Cav-3
are devoid of caveolae in muscle tissues (Drab et al., 2001; Gal-
biati et al., 2001; Razani et al., 2001). The putative functions of
caveolae include cholesterol transport, endocytosis, transcyto-
sis, and signal transduction. Physiologically, the loss of caveolae
results in impairment of cholesterol homeostasis, insulin sensi-
tivity, nitric oxide (NO) production, and calcium signaling and
defects in cardiopulmonary and vascular function (Cohen
et al., 2003; Frank et al., 2006; Razani et al., 2001). Interestingly,
mice deficient in Cav-1 exhibit resistance to atherosclerosis
despite a marked proatherogenic lipid profile, suggesting that
Cav-1 determines the athero-susceptibility of the vessel wall.
However, the precise mechanisms to explain this paradox
remain uncertain (Frank et al., 2004).
Recent findings have shown a complex role of Cav-1 during
the progression of atherosclerosis, depending on the cell types
examined (Frank and Lisanti, 2004). In ECs, Cav-1 and caveolae
may play a proatherogenic role by promoting transcytosis of
LDL-cholesterol particles from the blood to the subendothelial
space and by tonically inhibiting endothelial nitric oxide synthase
(eNOS) (Frank and Lisanti, 2004; Garcı´a-Carden˜a et al., 1996). In
contrast, in vascular smooth muscle cells (VSMCs), the ability of
Cav-1 to negatively regulate cell proliferation andmigration (neo-
intimal hyperplasia) may have an antiatherogenic effect (Hassan
et al., 2004, 2006). Recently, there was evidence that prolifera-
tion of VSMCs in human atherosclerosis is accompanied by a
reduction in Cav-1 expression (Schwencke et al., 2005), effects
also seen after arterial injury in rabbits (Peterson et al., 2003).
Finally, there is evidence that Cav-1 in monocytes/macrophages
influences phagocytosis (Li et al., 2005) and intracellular
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Caveolin-1 and AtherosclerosisFigure 1. Characterization of Cav-1 Expression in Arteries from ApoE/, ApoE/Cav-1/, and ApoE/Cav-1Rec Mice
(A) Cav-1 is present in ECs and VSMCs in atherosclerotic vessels from apoE/mice. Representative histological analysis of cross-sections from the aortic sinus
in phase contrast and costained with CD31 (endothelial marker), aSMC actin (vascular smooth muscle marker), and CD68 (macrophage marker).
(B) Protein levels of eNOS, Cav-1, and Cav-2 from mouse aorta. Hsp90 was used as a loading control.
(C) Immunostaining for Cav-1 in vessels from ApoE/, ApoE/Cav-1/, and ApoE/Cav-1Recmice showing the expression of endothelial marker CD31 (red)
and Cav-1 protein (green). The scale bars represent 100 mm.cholesterol metabolism (Frank et al., 2006), both pathways
that may influence atherogenesis. Thus, Cav-1 has the potential
to modulate all three major cell types involved in atherogenesis.
Here, we show using a genetic model that endothelial caveolae
are essential for the progression of atherosclerosis. Mechanisti-
cally, endothelial Cav-1 and caveolae are critical for LDL infiltra-
tion into the arterial wall, NO production, and macrophage
accumulation, all events necessary for atherogenesis. In addi-
tion, endothelial Cav-1 influences the hepatic clearance of
triglycerides (TGs) by regulating the size of liver EC fenestrations.
RESULTS AND DISCUSSION
Generation of Mice Lacking Cav-1 and ApoE
but Expressing Endothelial-Specific Cav-1
To dissect the specific role of Cav-1 during atherogenesis, we
analyzed the expression of Cav-1 in atherosclerotic plaques
from atherosclerosis-prone apolipoprotein E (ApoE) knockout
mice. As seen in Figure 1A, Cav-1 is highly expressed in CD31-
positive ECs (second panel) and to a lesser extent in VSMCs
(third panel). Undetectable levels of Cav-1 were found in macro-phages localized in atherosclerotic plaques (fourth panel).
Similar patterns of Cav-1 expression have been recently re-
ported in human atherosclerotic plaques (Rodriguez-Feo et al.,
2008). Since Cav-1 is highly expressed in endothelium, we
directly tested the role of endothelial-specific Cav-1/caveolae
by generating a mouse model that re-expresses Cav-1 in EC in
the absence of ApoE or Cav-1 (Figure S1). Figure 1B documents
protein expression in isolated aortae from these mice. In the
double knockout mice (ApoE/Cav-1/), Cav-1 and Cav-2
proteins were both absent due to the role of Cav-1 in stabilizing
Cav-2 protein levels (Parolini et al., 1999). Interestingly, in the
endothelial-specific reconstituted mice (ApoE/Cav-1Rec), the
expression of both Cav-1 and Cav-2 were restored in the endo-
thelium, where eNOS expression was used as EC marker. Next,
we examined Cav-1 reconstitution in the aortic endothelium
using immunofluorescence microscopy. As shown in Figure 1C,
ApoE/ (top panel) and ApoE/Cav-1Rec (bottom panel) mice
had relatively equal levels of immunoreactive Cav-1 in ECs as
defined by CD31 staining. ApoE/Cav-1/ vessels lacked
endothelial Cav-1 immunoreactivity without changing the levels
of CD31 (middle panel).Cell Metabolism 10, 48–54, July 8, 2009 ª2009 Elsevier Inc. 49
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Caveolin-1 and AtherosclerosisFigure 2. Endothelial-Specific Expression of Cav-1 Is Critical for the Progression of Atherosclerosis
(A) Representative examples of light microscopic images from ApoE/, ApoE/Cav-1/, and ApoE/Cav-1Rec aortic arches. Atherosclerotic plaques are
easily visualized by the white areas inside the arteries. The arrows indicate the innominate artery (1), left carotid artery (2), and left subclavian artery (3).
(B) Oil red O staining of aortas frommice with the indicated genotypes. Atheroma formation was significantly reduced in ApoE/Cav-1/mice (n = 9) compared
to ApoE/ mice (n = 22). Re-expression of Cav-1 in the endothelium (ApoE/Cav-1Rec, n = 10) promotes plaque formation in the double mutant mice.
(C) Representative histological analysis of aortic sinus stained with hematoxylin and eosin and oil red O from the indicated genotypes (n = 6). The scale bars
represent 200 mm.Endothelial-Specific Cav-1 Expression Is Essential
for the Progression of Atherosclerosis
To study the functional role of endothelial Cav-1 in atherogen-
esis, ApoE/, ApoE/Cav-1/, and ApoE/Cav-1Rec mice
were fed a high-cholesterol diet for 12 weeks. As in seen in Fig-
ure 2A, atherosclerotic plaques were clearly visible by light
microscopy in the aortic arch. Interestingly, the absence of
Cav-1 markedly reduces plaque formation in the carotid arteries,
and re-expression of Cav-1 in the endothelium restores athero-50 Cell Metabolism 10, 48–54, July 8, 2009 ª2009 Elsevier Inc.susceptibility in these sites. To quantify the extent of atheroscle-
rosis, aortas were opened longitudinally and stained en face with
oil red O to visualize lipid-laden atherosclerotic plaques. As
shown in Figure 2B, the absence of Cav-1 dramatically reduces
the number and size of aortic plaques, and the re-expression of
Cav-1 in the endothelium increases plaque formation in the
double mutant mice. Similar results were obtained in another
cohort of mice by analyzing the lesion areas in cross-sections
of the aortic sinus (Figure 2C).
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Caveolin-1 and AtherosclerosisEndothelial-Specific Cav-1 Expression Regulates LDL
Infiltration and Nitric Oxide Production
The above data suggest the presence of Cav-1 in endothelium is
necessary for the development of atherosclerosis. Since it is well
established that the transport of LDL cholesterol from the blood
into the artery wall is the initiating event that triggers atheroscle-
rosis (Glass andWitztum, 2001), we examined the importance of
EC Cav-1 in this process. Indeed, the perm-selectivity of the
endothelium to albumin and radiolabeled LDL is reduced in large
blood vessels, such as the aorta, in Cav-1-deficient mice (Frank
et al., 2008; Schubert et al., 2002). To test this directly, we exam-
ined LDL uptake and infiltration into vessels ofApoE/,ApoE/
Cav-1/, andApoE/Cav-1Recmiceafter jugular vein injections
of fluorescent DiI-LDL and monitored the accumulation of LDL
by en face imaging of the vessel wall. More DiI-LDL accumulated
in atherosclerosis-prone sites of the aortic arch (i.e., the lesser
curvature in the aortic arch) with respect to the thoracic aorta
(Figure 3A). The absence of Cav-1 caused a 3-fold decrease in
DiI-LDL infiltration in the aortic segments, an effect rescued by
Figure 3. Endothelial-Specific Cav-1 Regulates
LDL Entry into the Artery Wall and the NO Produc-
tion in ECs
(A) Immunofluorescence analysis of DiI-LDL infiltration in
different aortic segments. En face fluorescence images
of aortic sections from 6-week-old ApoE/ mice 30 min
after intravenous injection with DiI-LDL. The images
were captured using a 403 objective.
(B) En face fluorescence images of aortic sections from
6-week-old ApoE/, ApoE/Cav-1/, and ApoE/
Cav-1Rec mice 30 min after intravenous injection with DiI-
LDL.
(C) Quantification of DiI fluorescence intensity from en face
images. The data are quantified as fluorescence-positive
area versus total area. The data represent the mean ±
SEM; n = 5 mice in each group. * indicates p < 0.05
compared with ApoE/. The images were captured using
a 103 objective.
(D) NO release from WT, Cav-1/, and Cav-1Rec. The
nitrite accumulation was quantified for 8 hr. The data
represent the mean ± SEM of triplicate samples repeated
in three independent experiments. * indicates p < 0.05
compared with control.
the reintroduction of Cav-1 into the endothelium
(Figures 3B and 3C). Thus, Cav-1-dependent
caveolae regulate the entry of LDL into the
vessel wall.
The production of NO by vascular endothe-
lium is important for cardiovascular homeo-
stasis, as endogenous NO regulates many
fundamental processes (Sessa, 2004) and
impaired NO bioavailability is a commonly
used index of endothelial dysfunction in athero-
sclerosis (Busse and Fleming, 1996). Genetic
deletion of eNOS causes many cardiovascular
phenotypes, including accelerated atheroscle-
rosis (Kuhlencordt et al., 2001). Since endoge-
nous eNOS activation is under the tonic inhibi-
tory influence of Cav-1 as a negative regulator
of eNOS activity (Garcı´a-Carden˜a et al., 1996),
we directly examined the effect of Cav-1 on NO production using
EC fromWT,Cav-1/, andCav-1Recmice. As seen in Figure 3D,
the loss of Cav-1 increases NO production, while the re-expres-
sion of Cav-1 reduces the NO accumulation to the same levels as
WT cells. Thus, elevated production of NO by the endothelium
may also contribute to the reduced atherosclerosis observed in
the double mutant mice.
Increased Vessel Wall Inflammation and Macrophage
Infiltration Is Mediated by Endothelial-Specific Cav-1
To gain insights into how Cav-1 regulates the extent of athero-
genesis, we examined several additional potential mechanisms.
Activation of EC by proinflammatory cytokines occurs via the
expression of various leukocyte adhesion molecules, such as
vascular cell adhesion molecule 1 (VCAM-1), intracellular adhe-
sion molecule 1 (ICAM-1), and E-selectin, which capture and
transport circulating leukocytes to atherosclerotic lesions (Gal-
kina and Ley, 2007). To directly examine whether the loss of
Cav-1 influences adhesion molecule expression, the levels ofCell Metabolism 10, 48–54, July 8, 2009 ª2009 Elsevier Inc. 51
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Caveolin-1 and AtherosclerosisFigure 4. Loss of Cav-1 Alters the Expression Profile of Atherosclerosis-Related Genes and Macrophage Content in the Artery Wall
(A) Expression profile of atherosclerosis-related genes assessed by real-time PCR. Five independent qPCR reactions were carried out for each condition with
iCycler (BioRad). The n-fold change for each gene after diet compared to before diet was calculated. The data represent the mean ± SEM of quintuplicate
samples. Black bars correspond to ApoE/, white bars to ApoE/Cav-1/, and gray bars to ApoE/Cav-1Rec mice.
(B) Western blot analyses (left panel) and densitometry (right panel) of VCAM-1, ICAM-1, CD68, eNOS, pAkt-473, Akt, Actin, HSP-90, and Cav-1 in aortic extracts
prepared from ApoE/, ApoE/Cav-1/, and ApoE/Cav-1Recmice fed a high-cholesterol diet for 12 weeks. Results for four representative mice are shown
for each genotype. The data represent the mean ± SEM of quadruplicate samples.
(C) CD68-positive macrophages in lesions from ApoE/, ApoE/Cav-1/, and ApoE/Cav-1Recmice after 12 weeks of a high-cholesterol diet were detected
by CD68 staining. The data are quantified as CD68-positive area versus total lesion area (right panel). The data represent the mean ± SEM; n = 5 in each group.VCAM-1 and ICAM-1 were quantified by western blotting in ECs
isolated fromWT, Cav-1/, and Cav-1Recmice after stimulation
with TNF-a. As seen in Figures S2A and S2B, the absence of
Cav-1 causes a slight decrease, but not significant change, in
VCAM-1 and ICAM-1 expression, which is restored in EC from
Cav-1Rec mice. Similar results were obtained analyzing cell
surface protein expression for VCAM-1 and ICAM-1 by flow cy-
tometry (Figure S2C), and a greater reduction in the surface
expression of E-selectinwas found inCav-1/ECs (Figure S2C);
however, the absence or presence of Cav-1 did not influence the
proportional distribution of these adhesion molecules in ECs
using discontinuous sucrose gradients (Figure S2D). Next, we
analyzed the expression patterns of markers of inflammation in
the vessel wall of ApoE/, ApoE/Cav-1/, and ApoE/
Cav-1Rec mice before and after 3 months on a high-cholesterol
diet (i.e., fold change after diet) by quantitative PCR (qPCR) array
technology. As seen in Figures S3 and S4, the expression levels
of several inflammatorymolecules (VCAM-1, ICAM-1, E-selectin,
and P-selectin) and macrophage markers were significantly
downregulated in the ApoE/Cav-1/ mice compared to
ApoE/ alone and were confirmed using a different set of
primers (Figure 4A). The downregulation of these ‘‘proathero-
genic’’ genes in absence of Cav-1 was reversed in the endothe-
lial-specific reconstituted mice (ApoE/Cav-1Rec) and
confirmed by western blotting (Figure 4B, quantified in the right52 Cell Metabolism 10, 48–54, July 8, 2009 ª2009 Elsevier Inc.panel). However, enhanced inflammatory and macrophage-
specific gene expression did not influence the levels of eNOS
and Akt, important enzymes involved in the control of vascular
homeostasis (Figure 4B).
The enhanced expression of markers of inflammation sug-
gested that the levels of macrophage infiltration might differ in
the three strains. As seen in Figure 4C, the loss of Cav-1 reduces
macrophage accumulation (depicted by CD68-positive cells) in
plaques, whereas re-expression of Cav-1 in the endothelium
increases the macrophage infiltration in the ApoE/Cav-1/.
Collectively, these data demonstrate that endothelial Cav-1
influences LDL uptake, NO production, and macrophage accu-
mulation, leading to an augmented inflammatory plaque pheno-
type and larger lesions.
Endothelial-Specific Cav-1 Expression Reverses
the Dyslipidemia of the Double Mutant Mice
Finally, we examined multiple metabolic parameters of the mice.
Body weights were similar in all the groups of mice before and
after a high-cholesterol diet (Figure S5A). The absence of
Cav-1 increases plasma TG and cholesterol levels (Figure S5B)
as previously reported (Razani et al., 2002). Interestingly, the
re-expression of Cav-1 in the endothelium restores plasma TG
to normal levels and partially lowers cholesterol levels before
and after diet (Figures S5B and S5C). Next, lipoprotein profiles
Cell Metabolism
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cholesterol diet (Figures S5F and S5G) were analyzed. ApoB
containing lipoproteins as well as remnant lipoproteins (chylomi-
cron remnants, VLDL, and IDI/LDL-sized fractions) were
elevated in the double mutant mice (red line, ApoE/Cav-1/).
Interestingly, re-expression of Cav-1 in ECs (blue line) reverses
this ‘‘proatherogenic’’ lipoprotein profile in mice fed normal
chow or a high-cholesterol diet. Since the enhanced levels of
TG in Cav-1-deficient mice are not due to changes in lipoprotein
lipase (LPL) and/or hepatic lipase (HL) activity (Razani et al.,
2002), we further characterized the rate of liver VLDL-TG
synthesis in ApoE/, ApoE/Cav-1/, and ApoE/Cav-1Rec
mice using Triton WR-1339 (Otway and Robinson, 1967), which
inhibits LPL and therefore allows quantification of VLDL secre-
tion. As seen in Figure S6A, we did not observe any significant
differences between the different groups of mice analyzed, sug-
gesting that the clearance of VLDL/CMwas impaired in ApoE/
Cav-1/ mice. Moreover, the expression of genes involved in
the lipid synthesis and secretion of VLDL in the liver were also
similar in the two strains (Figure S6B).
It is appreciated that the morphology of hepatic sinusoids are
critical for the clearance of chylomicron remnants and postpran-
dial hyperlipemia (Cogger et al., 2008; Le Couteur et al., 2007;
Hilmer et al., 2005). The fenestrations of the liver sinusoid endo-
thelium cells (LSECs) influence the rate of substrate transfer
(including lipoproteins) between the sinusoidal blood, the space
of Disse, and hepatocytes (Fraser et al., 1995); thus, changes in
LSEC fenestrations or number have a significant impact on
hepatic clearance functions. Cav-1 can be found in fenestrations
of isolated LSECs (Cogger et al., 2008) and in rat liver using
immunogold microscopy (Ogi et al., 2003). Similarly, we found
Cav-1 in LSEC of ApoE/ but not ApoE/Cav-1/ mice with
immunogold electron microscopy (Figure S7). To determine
whether the absence or presence of Cav-1 influences LSEC
fenestrations, we analyzed sinusoid morphology using scanning
electron microscope. As seen in Figure S8A, quantitative EM
studies indicate that Cav-1 changes the porosity of the LSEC,
indexed by a reduction in the diameter but not in the frequency
of fenestrations (Figures S8B and S8C). The idea that Cav-1
regulates SEC porosity is supported by the correlation between
sinusoid pseudocapillarization and the levels of hepatic Cav-1
(Jamieson et al., 2007). Thus, the reduced clearance of TG in
ApoE/Cav-1/ mice is likely due to pseudocapillarization of
the SEC.
The major finding of this study is that endothelial caveolae
regulate the portals of entry for LDL into the vessel wall, since
transgenic expression of endothelial Cav-1 reverts the typically
atheroprotected ApoE/Cav-1/ mouse to an atheroprone
mouse. Mechanistically, we show that Cav-1 controls LDL
uptake, endothelial NO levels, and the expression of vascular
adhesion molecules that promote macrophage infiltration. Early
EM studies examining LDL transport across the endothelium
documented the uptake of LDL via two routes: a saturable, cla-
thrin-mediated endocytic mechanism via the LDL- receptor; and
a fluid-phase nonsaturable transcytotic mechanism through
noncoated plasmalemmal vesicles, perhaps caveolae (Simio-
nescu and Simionescu, 1991). Although Cav-1 is expressed in
several cell types (ECs, macrophages, VSMCs, and fibroblasts)
implicated in the pathogenesis of atherosclerosis, Cav-1 in ECis sufficient to promote lesion development. Thus, our findings
provide an important in vivo demonstration that EC Cav-1 regu-
lates the entry of LDL to promote atherogenesis.
EXPERIMENTAL PROCEDURES
Materials and additional methods are available in the Supplemental Experi-
mental Procedures.
Animal Procedures
Cav-1/ mice were generated as previously described (Drab et al., 2001).
Cav1/ mice that have been backcrossed six generations onto a C57BL/6
background were crossed with ApoE-deficient mice, also on the C57BL/6
background, to generate mice heterozygous at both loci. These ApoE+/
Cav1+/ mice were crossed a second time with ApoE/ mice. The ApoE/
Cav1/+ progeny from this round of breeding were then intercrossed to
produce ApoE/Cav1/ and ApoE/Cav1+/+ littermates that were used
as controls for all studies. Endothelial-specific Cav-1 TG mice carrying canine
Cav-1 transgene under the preproendothelin-1 promoter were crossed six
generations with F6 generation Cav-1/, as reported previously (Yu et al.,
2006). Accelerated atherosclerosis was induced by feeding the mice for
14 weeks with a high-fat Western-type diet containing 1.25% cholesterol
(D12108; ResearchDiets, Inc.; New Brunswick, NJ). The Institutional Animal
Care Use Committee of Yale University approved all the experiments.
Atherosclerotic Lesion Analysis
After 12 weeks of being fed a Western-type diet, mice were anesthetized and
euthanized. Mouse hearts were perfused using 10 ml of PBS (Invitrogen) fol-
lowed by 10 ml of 4% paraformaldehyde (PFA). After incubation in 4% PFA
overnight, the adventitia was thoroughly cleaned under a dissecting micro-
scope, and the aorta was cut open longitudinally and pinned onto a silicone
plate. To calculate the lesion area, aortas were stained with oil red O (Sigma)
before the analysis. Oil red stock solution (35 ml; 0.2% w/v in methanol) was
mixed with 10 ml of 1 M NaOH and filtered. Aortas were briefly rinsed with
78% methanol, incubated in oil red O solution for 50 min, destained in 78%
methanol for 5 min, and mounted on microscopic slides using aqueous
mounting medium (Stephens Scientific; Wayne, NJ). Plaques were analyzed
under the Nikon SMZ 1000 microscope, connected to a Kodak DC290 digital
camera. The images were analyzed using Adobe Photoshop 6.0 (Adobe), and
the lesions were quantified using the ImageJ (NIH) program. For other images,
10 mm thick cryosections of the proximal aorta were serially sectioned and
stained with hematoxylin and eosin for quantifications of the lesion areas using
ImageJ. Aortic lesion size of each animal was obtained by averaging lesion
areas in six sections from the same mouse.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and eight figures and can be found online at http://www.
cell.com/cell-metabolism/supplemental/S1550-4131(09)00161-2.
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